226 related articles for article (PubMed ID: 27863176)
1. Translational Pharmacokinetic/Pharmacodynamic Modeling of Tumor Growth Inhibition Supports Dose-Range Selection of the Anti-PD-1 Antibody Pembrolizumab.
Lindauer A; Valiathan CR; Mehta K; Sriram V; de Greef R; Elassaiss-Schaap J; de Alwis DP
CPT Pharmacometrics Syst Pharmacol; 2017 Jan; 6(1):11-20. PubMed ID: 27863176
[TBL] [Abstract][Full Text] [Related]
2. Model-Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors.
Ahamadi M; Freshwater T; Prohn M; Li CH; de Alwis DP; de Greef R; Elassaiss-Schaap J; Kondic A; Stone JA
CPT Pharmacometrics Syst Pharmacol; 2017 Jan; 6(1):49-57. PubMed ID: 27863186
[TBL] [Abstract][Full Text] [Related]
3. Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors.
Patnaik A; Kang SP; Rasco D; Papadopoulos KP; Elassaiss-Schaap J; Beeram M; Drengler R; Chen C; Smith L; Espino G; Gergich K; Delgado L; Daud A; Lindia JA; Li XN; Pierce RH; Yearley JH; Wu D; Laterza O; Lehnert M; Iannone R; Tolcher AW
Clin Cancer Res; 2015 Oct; 21(19):4286-93. PubMed ID: 25977344
[TBL] [Abstract][Full Text] [Related]
4. Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab-Treated Advanced Melanoma.
Chatterjee MS; Elassaiss-Schaap J; Lindauer A; Turner DC; Sostelly A; Freshwater T; Mayawala K; Ahamadi M; Stone JA; de Greef R; Kondic AG; de Alwis DP
CPT Pharmacometrics Syst Pharmacol; 2017 Jan; 6(1):29-39. PubMed ID: 27896938
[TBL] [Abstract][Full Text] [Related]
5. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.
Robert C; Ribas A; Wolchok JD; Hodi FS; Hamid O; Kefford R; Weber JS; Joshua AM; Hwu WJ; Gangadhar TC; Patnaik A; Dronca R; Zarour H; Joseph RW; Boasberg P; Chmielowski B; Mateus C; Postow MA; Gergich K; Elassaiss-Schaap J; Li XN; Iannone R; Ebbinghaus SW; Kang SP; Daud A
Lancet; 2014 Sep; 384(9948):1109-17. PubMed ID: 25034862
[TBL] [Abstract][Full Text] [Related]
6. Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose.
de Vries Schultink AHM; Doornbos RP; Bakker ABH; Bol K; Throsby M; Geuijen C; Maussang D; Schellens JHM; Beijnen JH; Huitema ADR
Invest New Drugs; 2018 Dec; 36(6):1006-1015. PubMed ID: 29728897
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer.
McDermott J; Jimeno A
Drugs Today (Barc); 2015 Jan; 51(1):7-20. PubMed ID: 25685857
[TBL] [Abstract][Full Text] [Related]
8. Preclinical evaluation of the efficacy, pharmacokinetics and immunogenicity of JS-001, a programmed cell death protein-1 (PD-1) monoclonal antibody.
Fu J; Wang F; Dong LH; Zhang J; Deng CL; Wang XL; Xie XY; Zhang J; Deng RX; Zhang LB; Wu H; Feng H; Chen B; Song HF
Acta Pharmacol Sin; 2017 May; 38(5):710-718. PubMed ID: 28317872
[TBL] [Abstract][Full Text] [Related]
9. Dose Rationalization of Pembrolizumab and Nivolumab Using Pharmacokinetic Modeling and Simulation and Cost Analysis.
Ogungbenro K; Patel A; Duncombe R; Nuttall R; Clark J; Lorigan P
Clin Pharmacol Ther; 2018 Apr; 103(4):582-590. PubMed ID: 28913853
[TBL] [Abstract][Full Text] [Related]
10. MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models.
Leow CC; Coffman K; Inigo I; Breen S; Czapiga M; Soukharev S; Gingles N; Peterson N; Fazenbaker C; Woods R; Jallal B; Ricketts SA; Lavallee T; Coats S; Chang Y
Int J Oncol; 2012 May; 40(5):1321-30. PubMed ID: 22327175
[TBL] [Abstract][Full Text] [Related]
11. Blood Assay Predicts Response to Pembrolizumab.
Cancer Discov; 2016 Nov; 6(11):1200. PubMed ID: 27698203
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of MEDI0680, a fully human anti-PD-1 monoclonal antibody, in patients with advanced malignancies.
Song X; Khan AA; Zhou D; Elgeioushi N; Walcott F; Ren S; Gibbs M
Cancer Chemother Pharmacol; 2022 Mar; 89(3):373-382. PubMed ID: 35133489
[TBL] [Abstract][Full Text] [Related]
13. Safety of pembrolizumab for the treatment of melanoma.
Martin-Liberal J; Kordbacheh T; Larkin J
Expert Opin Drug Saf; 2015 Jun; 14(6):957-64. PubMed ID: 25927979
[TBL] [Abstract][Full Text] [Related]
14. Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody.
Stewart R; Morrow M; Hammond SA; Mulgrew K; Marcus D; Poon E; Watkins A; Mullins S; Chodorge M; Andrews J; Bannister D; Dick E; Crawford N; Parmentier J; Alimzhanov M; Babcook JS; Foltz IN; Buchanan A; Bedian V; Wilkinson RW; McCourt M
Cancer Immunol Res; 2015 Sep; 3(9):1052-62. PubMed ID: 25943534
[TBL] [Abstract][Full Text] [Related]
15. Dosage Optimization of Nemolizumab Using Population Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Modeling and Simulation.
Saito T; Iida S; Terao K; Kumagai Y
J Clin Pharmacol; 2017 Dec; 57(12):1564-1572. PubMed ID: 28703903
[TBL] [Abstract][Full Text] [Related]
16. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells.
John LB; Devaud C; Duong CP; Yong CS; Beavis PA; Haynes NM; Chow MT; Smyth MJ; Kershaw MH; Darcy PK
Clin Cancer Res; 2013 Oct; 19(20):5636-46. PubMed ID: 23873688
[TBL] [Abstract][Full Text] [Related]
17. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade.
Ayers M; Lunceford J; Nebozhyn M; Murphy E; Loboda A; Kaufman DR; Albright A; Cheng JD; Kang SP; Shankaran V; Piha-Paul SA; Yearley J; Seiwert TY; Ribas A; McClanahan TK
J Clin Invest; 2017 Aug; 127(8):2930-2940. PubMed ID: 28650338
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab for the treatment of melanoma.
Kumar SS; McNeil CM
Expert Rev Clin Pharmacol; 2015; 8(5):515-27. PubMed ID: 26146011
[TBL] [Abstract][Full Text] [Related]
19. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response.
Huang AC; Postow MA; Orlowski RJ; Mick R; Bengsch B; Manne S; Xu W; Harmon S; Giles JR; Wenz B; Adamow M; Kuk D; Panageas KS; Carrera C; Wong P; Quagliarello F; Wubbenhorst B; D'Andrea K; Pauken KE; Herati RS; Staupe RP; Schenkel JM; McGettigan S; Kothari S; George SM; Vonderheide RH; Amaravadi RK; Karakousis GC; Schuchter LM; Xu X; Nathanson KL; Wolchok JD; Gangadhar TC; Wherry EJ
Nature; 2017 May; 545(7652):60-65. PubMed ID: 28397821
[TBL] [Abstract][Full Text] [Related]
20. The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis.
Zhang T; Xie J; Arai S; Wang L; Shi X; Shi N; Ma F; Chen S; Huang L; Yang L; Ma W; Zhang B; Han W; Xia J; Chen H; Zhang Y
Oncotarget; 2016 Nov; 7(45):73068-73079. PubMed ID: 27683031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
